<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235560</url>
  </required_header>
  <id_info>
    <org_study_id>0402008</org_study_id>
    <secondary_id>GOELAMS</secondary_id>
    <secondary_id>PHRC</secondary_id>
    <nct_id>NCT00235560</nct_id>
  </id_info>
  <brief_title>Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients</brief_title>
  <acronym>LAM-RAPA</acronym>
  <official_title>Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients. A Study From the Groupe Ouest Est d'étude Des Leucémies Aiguës Myéloïdes (GOELAMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      These study is designed to evaluate the tolerability and efficacy of sirolimus (rapamycin) in
      combination with low-dose aracytin in elderly AML.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose
      aracytin
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bioclinical markers of response</measure>
  </secondary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rapamycin</intervention_name>
    <description>sirolimus</description>
    <other_name>RAPAMUNE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 60 y.

          -  Informed consent

          -  de novo or secondary LAM(CML excluded) not elligible for intensive chemotherapy.

          -  Previously untreated

        Exclusion Criteria:

          -  Renal impairment (serum creatinin &gt;2N)

          -  Hepatic impairment (TGO ou TGP &gt; 5N), une cholestase (Phosphatases Alcalines or
             gamma-GT &gt; 5N),bilirubin &gt; 3N

               -  Blast crisis CML

               -  Acute Promyelocytic Leukemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RECHER Christian</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'Hématologie, CHU</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie, Hôpital Jean Minjoz</name>
      <address>
        <city>BESANçON</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Récher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, Benzaquen D, Laurent G, Huguet F, Payrastre B. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2005 Mar 15;105(6):2527-34. Epub 2004 Nov 18.</citation>
    <PMID>15550488</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>October 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2005</study_first_posted>
  <last_update_submitted>June 19, 2008</last_update_submitted>
  <last_update_submitted_qc>June 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>LLAU Marie-Elise</name_title>
    <organization>University Hospital Toulouse</organization>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Rapamycin</keyword>
  <keyword>Elderly</keyword>
  <keyword>Elderly patients not eligible for intensive chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

